Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients
Phase 2
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Combination Product: continuous oral delivery of levodopa/carbidopa
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- SynAgile Corporation
- Target Recruit Count
- 17
- Registration Number
- NCT04778176
- Locations
- 🇮🇹
Centro Parkinson, Policlinico Tor Vergata, Rome, Italy
🇮🇹San Raffaele Cassino, Cassino, Italy
🇮🇹IRCCS San Raffaele Pisana, Rome, Italy
© Copyright 2025. All Rights Reserved by MedPath